BWAY
Price
$14.10
Change
-$0.96 (-6.37%)
Updated
Jul 13 closing price
Capitalization
575.55M
29 days until earnings call
Intraday BUY SELL Signals
DXR
Price
$10.21
Change
+$0.05 (+0.49%)
Updated
Jul 13 closing price
Capitalization
59.03M
37 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BWAY vs DXR

BWAY vs DXR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BWAY vs. DXR commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BWAY is a Buy and DXR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (BWAY: $14.10 vs. DXR: $10.21)
Brand notoriety: BWAY and DXR are both not notable
BWAY represents the Medical/Nursing Services, while DXR is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: BWAY: 58% vs. DXR: 8%
Market capitalization -- BWAY: $575.55M vs. DXR: $59.03M
BWAY [@Medical/Nursing Services] is valued at $575.55M. DXR’s [@Pharmaceuticals: Other] market capitalization is $59.03M. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $160.44B to $0. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $144.19B to $0. The average market capitalization across the [@Medical/Nursing Services] industry is $5.64B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $7.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BWAY’s FA Score shows that 0 FA rating(s) are green whileDXR’s FA Score has 0 green FA rating(s).

  • BWAY’s FA Score: 0 green, 5 red.
  • DXR’s FA Score: 0 green, 5 red.
According to our system of comparison, BWAY is a better buy in the long-term than DXR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BWAY’s TA Score shows that 3 TA indicator(s) are bullish while DXR’s TA Score has 4 bullish TA indicator(s).

  • BWAY’s TA Score: 3 bullish, 6 bearish.
  • DXR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, DXR is a better buy in the short-term than BWAY.

Price Growth

BWAY (@Medical/Nursing Services) experienced а -11.99% price change this week, while DXR (@Pharmaceuticals: Other) price change was -1.73% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +7.62%. For the same industry, the average monthly price growth was -1.16%, and the average quarterly price growth was -16.57%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.39%. For the same industry, the average monthly price growth was +7.29%, and the average quarterly price growth was -8.66%.

Reported Earning Dates

BWAY is expected to report earnings on Aug 12, 2026.

DXR is expected to report earnings on Aug 20, 2026.

Industries' Descriptions

@Medical/Nursing Services (+7.62% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

@Pharmaceuticals: Other (-2.39% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BWAY($576M) has a higher market cap than DXR($59M). BWAY has higher P/E ratio than DXR: BWAY (64.18) vs DXR (6.16). BWAY YTD gains are higher at: 48.265 vs. DXR (-30.780). DXR has less debt than BWAY: DXR (263K) vs BWAY (6.71M). BWAY has higher revenues than DXR: BWAY (56.2M) vs DXR (10.3M).
BWAYDXRBWAY / DXR
Capitalization576M59M976%
EBITDA10.8MN/A-
Gain YTD48.265-30.780-157%
P/E Ratio64.186.161,041%
Revenue56.2M10.3M546%
Total Cash59.8MN/A-
Total Debt6.71M263K2,550%
FUNDAMENTALS RATINGS
BWAY vs DXR: Fundamental Ratings
BWAY
DXR
OUTLOOK RATING
1..100
8146
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
62100
SMR RATING
1..100
6442
PRICE GROWTH RATING
1..100
3957
P/E GROWTH RATING
1..100
35100
SEASONALITY SCORE
1..100
5022

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BWAY's Valuation (77) in the Medical Specialties industry is in the same range as DXR (81). This means that BWAY’s stock grew similarly to DXR’s over the last 12 months.

BWAY's Profit vs Risk Rating (62) in the Medical Specialties industry is somewhat better than the same rating for DXR (100). This means that BWAY’s stock grew somewhat faster than DXR’s over the last 12 months.

DXR's SMR Rating (42) in the Medical Specialties industry is in the same range as BWAY (64). This means that DXR’s stock grew similarly to BWAY’s over the last 12 months.

BWAY's Price Growth Rating (39) in the Medical Specialties industry is in the same range as DXR (57). This means that BWAY’s stock grew similarly to DXR’s over the last 12 months.

BWAY's P/E Growth Rating (35) in the Medical Specialties industry is somewhat better than the same rating for DXR (100). This means that BWAY’s stock grew somewhat faster than DXR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BWAYDXR
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
66%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
64%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
69%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
70%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
68%
Advances
ODDS (%)
Bullish Trend 19 days ago
84%
Bullish Trend 5 days ago
66%
Declines
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 18 days ago
73%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
80%
Aroon
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
BWAY
Daily Signal:
Gain/Loss:
DXR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OYRDX30.39N/A
N/A
Invesco Rising Dividends Y
FDYNX155.19N/A
N/A
Franklin DynaTech C
VMSGX23.77N/A
N/A
VALIC Company I Mid Cap Strategic Gr
FCVFX39.95N/A
N/A
Fidelity Advisor Value C
MSSVX10.24N/A
N/A
AMG Frontier Small Cap Growth N

BWAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, BWAY has been loosely correlated with DCTH. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if BWAY jumps, then DCTH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BWAY
1D Price
Change %
BWAY100%
-6.37%
DCTH - BWAY
33%
Loosely correlated
-1.08%
ISRG - BWAY
31%
Poorly correlated
+0.08%
STIM - BWAY
29%
Poorly correlated
+1.70%
ITGR - BWAY
28%
Poorly correlated
+2.88%
PRCT - BWAY
28%
Poorly correlated
+1.58%
More

DXR and

Correlation & Price change

A.I.dvisor tells us that DXR and IART have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DXR and IART's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DXR
1D Price
Change %
DXR100%
+0.49%
IART - DXR
33%
Poorly correlated
-1.12%
BWAY - DXR
27%
Poorly correlated
-6.37%
AVTR - DXR
23%
Poorly correlated
+1.64%
COO - DXR
20%
Poorly correlated
+0.88%
SHC - DXR
20%
Poorly correlated
-1.36%
More